

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SVLSF IV, LLC</u> (Last) (First) (Middle) ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 (Street) BOSTON MA 02108 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/03/2013	3. Issuer Name and Ticker or Trading Symbol <u>SafeStitch Medical, Inc. [SFES.OB]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock ⁽¹⁾	22,433,674	I	See footnote ⁽¹⁾⁽⁵⁾
Common Stock ⁽²⁾	22,433,674	I	See footnote ⁽²⁾⁽⁵⁾
Common Stock ⁽³⁾	21,814,352	D	
Common Stock ⁽⁴⁾	619,322	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Convertible Preferred Stock ⁽¹⁾⁽⁶⁾⁽⁷⁾	09/03/2013	(8)	Common Stock	11,549,790	0.4 ⁽⁶⁾⁽⁷⁾	I	See footnote ⁽¹⁾⁽⁵⁾
Series B Convertible Preferred Stock ⁽²⁾⁽⁶⁾⁽⁷⁾	09/03/2013	(8)	Common Stock	11,549,790	0.4 ⁽⁶⁾⁽⁷⁾	I	See footnote ⁽²⁾⁽⁵⁾
Series B Convertible Preferred Stock ⁽³⁾⁽⁶⁾	09/03/2013	(8)	Common Stock	11,230,935	0.4 ⁽⁶⁾	D	
Series B Convertible Preferred Stock ⁽⁴⁾⁽⁷⁾	09/03/2013	(8)	Common Stock	318,855	0.4 ⁽⁷⁾	D	

1. Name and Address of Reporting Person* <u>SVLSF IV, LLC</u> (Last) (First) (Middle) ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 (Street) BOSTON MA 02108 (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* <u>SV LIFE SCIENCES FUND IV, L.P.</u> (Last) (First) (Middle) ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 (Street) BOSTON MA 02108 (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person*

SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.

(Last) (First) (Middle)

ONE BOSTON PLACE
201 WASHINGTON STREET, SUITE 3900

(Street)

BOSTON MA 02108

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SV Life Sciences Fund IV (GP), L.P.

(Last) (First) (Middle)

ONE BOSTON PLACE
201 WASHINGTON STREET, SUITE 3900

(Street)

BOSTON MA 02108

(City) (State) (Zip)

Explanation of Responses:

1. These shares are owned directly by SV Life Sciences Fund IV, L.P. ("SVLS IV LP") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Strategic Partners"). SV Life Sciences Fund IV (GP), L.P. ("SVLS IV GP"), the general partner of SVLS IV LP and Strategic Partners, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLS IV GP disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest therein.
2. These shares are owned directly by SVLS IV LP and Strategic Partners. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLSF IV, LLC disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest therein.
3. These shares are held directly by SVLS IV LP.
4. These shares are held directly by Strategic Partners.
5. SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein.
6. On September 3, 2013, SafeStitch Medical, Inc. (the "Issuer") sold and issued to SVLS IV LP, in a privately negotiated transaction pursuant to a securities purchase agreement, an aggregate of 1,123,093.5 shares of the Issuer's Series B Convertible Preferred Stock at a purchase price of \$4.00 per share. Upon the filing of an Amendment to the Issuer's Certificate of Incorporation with the State of Delaware, each share of the Issuer's Series B Convertible Preferred Stock will automatically convert into ten (10) shares of the Issuer's common stock.
7. On September 3, 2013, the Issuer sold and issued to Strategic Partners, in a privately negotiated transaction pursuant to a securities purchase agreement, an aggregate of 31,885.5 shares of the Issuer's Series B Convertible Preferred Stock at a purchase price of \$4.00 per share. Upon the filing of an Amendment to the Issuer's Certificate of Incorporation with the State of Delaware, each share of the Issuer's Series B Convertible Preferred Stock will automatically convert into ten (10) shares of the Issuer's common stock.
8. The Series B Convertible Preferred Stock has no expiration date.

/s/ Thomas B. Rosedale 09/11/2013
(pursuant to power of attorney)

/s/ Thomas B. Rosedale 09/11/2013
(pursuant to power of attorney)

/s/ Thomas B. Rosedale 09/11/2013
(pursuant to power of attorney)

/s/ Thomas B. Rosedale 09/11/2013
(pursuant to power of attorney)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

OF

SVLSF IV, LLC

This statement confirms that the undersigned has authorized and designated each of Suzanne Hamel and Thomas B. Rosedale his attorneys-in-fact to (i) prepare, execute and file on behalf of the undersigned Form ID or any other necessary documents or forms in order to obtain access codes (including, without limitation, CIK and CCC codes) for the undersigned to permit filing on EDGAR, and (ii) prepare, execute and file on behalf of the undersigned all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of a public reporting company or by virtue of the undersigned holding board of director or executive officer positions with a public reporting company. The authority of such attorneys under this Power of Attorney shall continue until the undersigned is no longer required to file Forms 3, 4 and 5 with the U.S. Securities and Exchange Commission, unless earlier revoked in writing. The undersigned acknowledges that such attorneys are not assuming any of the undersigned's responsibilities to comply with the requirements of Section 16 of the Securities Exchange Act of 1934, as amended, or any of the undersigned's liabilities for failure to comply with such requirements.

SVLSF IV, LLC

Date: August 22, 2013

_____/s/ Denise W. Marks_____
Name: Denise W. Marks
Title: Member

LIMITED POWER OF ATTORNEY

OF

SV LIFE SCIENCES FUND IV, L.P.

This statement confirms that the undersigned has authorized and designated each of Suzanne Hamel and Thomas B. Rosedale his attorneys-in-fact to (i) prepare, execute and file on behalf of the undersigned Form ID or any other necessary documents or forms in order to obtain access codes (including, without limitation, CIK and CCC codes) for the undersigned to permit filing on EDGAR, and (ii) prepare, execute and file on behalf of the undersigned all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of a public reporting company or by virtue of the undersigned holding board of director or executive officer positions with a public reporting company. The authority of such attorneys under this Power of Attorney shall continue until the undersigned is no longer required to file Forms 3, 4 and 5 with the U.S. Securities and Exchange Commission, unless earlier revoked in writing. The undersigned acknowledges that such attorneys are not assuming any of the undersigned's responsibilities to comply with the requirements of Section 16 of the Securities Exchange Act of 1934, as amended, or any of the undersigned's liabilities for failure to comply with such requirements.

SV LIFE SCIENCES FUND IV, L.P.

By: SV Life Sciences Fund IV (GP), L.P.,
its Sole General Partner
By: SVLSF IV, LLC, its sole General
Partner

Date: August 22, 2013

_/s/ Denise W. Marks _____
Name: Denise W. Marks
Title: Member

LIMITED POWER OF ATTORNEY

OF

SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L.P.

This statement confirms that the undersigned has authorized and designated each of Suzanne Hamel and Thomas B. Rosedale his attorneys-in-fact to (i) prepare, execute and file on behalf of the undersigned Form ID or any other necessary documents or forms in order to obtain access codes (including, without limitation, CIK and CCC codes) for the undersigned to permit filing on EDGAR, and (ii) prepare, execute and file on behalf of the undersigned all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of a public reporting company or by virtue of the undersigned holding board of director or executive officer positions with a public reporting company. The authority of such attorneys under this Power of Attorney shall continue until the undersigned is no longer required to file Forms 3, 4 and 5 with the U.S. Securities and Exchange Commission, unless earlier revoked in writing. The undersigned acknowledges that such attorneys are not assuming any of the undersigned's responsibilities to comply with the requirements of Section 16 of the Securities Exchange Act of 1934, as amended, or any of the undersigned's liabilities for failure to comply with such requirements.

SV LIFE SCIENCES FUND IV
STRATEGIC PARTNERS, L.P.

By: SV Life Sciences Fund IV (GP), L.P.,
its Sole General Partner
By: SVLSF IV, LLC, its sole General
Partner

Date: August 22, 2013

_/s/ Denise W. Marks _____
Name: Denise W. Marks
Title: Member

LIMITED POWER OF ATTORNEY

OF

SV LIFE SCIENCES FUND IV (GP), L.P.

This statement confirms that the undersigned has authorized and designated each of Suzanne Hamel and Thomas B. Rosedale his attorneys-in-fact to (i) prepare, execute and file on behalf of the undersigned Form ID or any other necessary documents or forms in order to obtain access codes (including, without limitation, CIK and CCC codes) for the undersigned to permit filing on EDGAR, and (ii) prepare, execute and file on behalf of the undersigned all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of a public reporting company or by virtue of the undersigned holding board of director or executive officer positions with a public reporting company. The authority of such attorneys under this Power of Attorney shall continue until the undersigned is no longer required to file Forms 3, 4 and 5 with the U.S. Securities and Exchange Commission, unless earlier revoked in writing. The undersigned acknowledges that such attorneys are not assuming any of the undersigned's responsibilities to comply with the requirements of Section 16 of the Securities Exchange Act of 1934, as amended, or any of the undersigned's liabilities for failure to comply with such requirements.

SV LIFE SCIENCES FUND IV (GP), L.P.

By: SVLSF IV, LLC, its sole General Partner

Date: August 22, 2013

_/s/ Denise W. Marks _____
Name: Denise W. Marks
Title: Member